APOLLO ENDOSURGERY UK LTD

• ⚠

  Material uncertainty over going concern

  From November 2023 the trade and assets of the business were transferred to Boston Scientific Limited and other Boston Scientific group companies and the company has ceased trading. As the directors do not intend to acquire an alternative trade, these accounts have not been prepared on the going concern basis. No material adjustments were necessary to the amount at which net assets are included in these financial statements to reflect differences between the book value and its amounts expected to be realised for assets or incurred as liabilities. The company considers due to parental support that it has sufficient funds to settle any future liabilities as they fall due.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -100%

  £20,662,113 → £0

  lowest in 4 filed years

• Cash

  -85.7%

  £3,778,269 → £541,323

  lowest in 4 filed years

• Net assets

  -5.9%

  £20,500,465 → £19,290,047

• Employees

  -97.6%

  42 → 1

  lowest in 4 filed years

• Operating profit

  -106.8%

  £17,613,370 → -£1,199,106

  lowest in 4 filed years

• Profit before tax

  -106.8%

  £17,613,370 → -£1,199,106

  lowest in 4 filed years

• Wages

  -99.8%

  £4,040,726 → £6,627

  lowest in 4 filed years

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Armstrong Watson Audit Limted

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“From November 2023 the trade and assets of the business were transferred to Boston Scientific Limited and other Boston Scientific group companies and the company has ceased trading. As the directors do not intend to acquire an alternative trade, these accounts have not been prepared on the going concern basis. No material adjustments were necessary to the amount at which net assets are included in these financial statements to reflect differences between the book value and its amounts expected to be realised for assets or incurred as liabilities. The company considers due to parental support that it has sufficient funds to settle any future liabilities as they fall due.”

Significant events

• “Effective 4 April 2023, Apollo Endosurgery, Inc., the company's ultimate parent company, was acquired by Boston Scientific Corporation ('BSC'), a corporation incorporated in Delaware, U.S.A. From November 2023 the trade and assets of the business were transferred to Boston Scientific Limited and other Boston Scientific group companies and the company has ceased trading. The directors do not wish to find an alternative trade, therefore the business will be liquidated or struck off at a future date.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.